SLC5A2 and chronic kidney disease: Cardiovascular and renal outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) remain poor despite the use of standard pharmacotherapy, including angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and sodium-glucose cotransporter 2 (SGLT2) inhibitors [1, 2].